Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Kristie A. Blum, Rebecca Auer et al.|New England Journal of Medicine|2013Cited by 1.7k
Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-upMichael Wang, Kristie A. Blum, Simon Rule et al.|Blood|2012Cited by 26